Milowsky, Matthew I.

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 1,065

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 303

Trends in stage‐specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006

Nielsen, M. E., Smith, A. B., Meyer, A., Kuo, T., Tyree, S., Kim, W. Y., Milowsky, M. I., Pruthi, R. S., & Millikan, R. C. (2014) · Cancer

Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology Studies

Cited by 149

Somatic mutation of fibroblast growth factor receptor‐3 ( FGFR3 ) defines a distinct morphological subtype of high‐grade urothelial carcinoma

Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology

Bladder and Urothelial Cancer TreatmentsFibroblast Growth Factor Research

Cited by 88

Entinostat induces antitumor immune responses through immune editing of tumor neoantigens

Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 84

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

Milowsky, M. I., Galsky, M. D., Morris, M. J., Crona, D. J., George, D. J., Dreicer, R., Tse, K., Petruck, J., Webb, I. J., Bander, N. H., et al. (2016) · Urologic Oncology: Seminars and Original Investigations

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 78

Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma

Krishnan, B., Rose, T. L., Kardos, J., Milowsky, M. I., & Kim, W. Y. (2016) · JAMA Oncology

Renal cell carcinoma treatmentCancer Genomics and Diagnostics

Cited by 75

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research

Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations

Cited by 12